PURPOSE: The study objective was to investigate and validate plasma growth differentiation factor-15 (GDF-15) as a predictor of lymph node metastasis and a poor prognosis in primary endometrial cancer. EXPERIMENTAL DESIGN: Plasma samples from 510 women treated for endometrial cancer in a primary investigation cohort (n = 44) and a secondary validation cohort (n = 466) were analyzed for GDF-15. Plasma from healthy premenopausal (n = 20) and postmenopausal (n = 20) women, women with borderline (n = 43), benign (n = 144), and malignant ovarian tumors (n = 125) were used for comparison. RESULTS: Median plasma GDF-15 concentration for the endometrial cancer group was elevated (1,077 ng/L) as compared with pre- and postmenopausal controls (590 and 684 ng/L) and women with benign (591 ng/L) or borderline ovarian tumors (718 ng/L; all P < 0.001), but similar to the ovarian cancer group. In the large validation cohort of endometrial carcinomas, high plasma GDF-15 was significantly associated with International Federation of Gynecology and Obstetrics (FIGO) stage III/IV disease, nonendometrioid histology, high grade, older age, postmenopausal status, and lymph node metastases (all P ≤ 0.001). High GDF-15 was also an independent predictor of poor disease-specific and recurrence-free survival. CONCLUSIONS: Based on findings indicated in a primary investigation set and confirmed in the large secondary validation set, we report for the first time plasma GDF-15 as a biomarker for endometrial cancer phenotype, including presence of lymph node metastasis and reduced survival. Its applicability as a predictor of metastatic nodes and in monitoring treatment of endometrial cancer needs to be further studied.
PURPOSE: The study objective was to investigate and validate plasma growth differentiation factor-15 (GDF-15) as a predictor of lymph node metastasis and a poor prognosis in primary endometrial cancer. EXPERIMENTAL DESIGN: Plasma samples from 510 women treated for endometrial cancer in a primary investigation cohort (n = 44) and a secondary validation cohort (n = 466) were analyzed for GDF-15. Plasma from healthy premenopausal (n = 20) and postmenopausal (n = 20) women, women with borderline (n = 43), benign (n = 144), and malignant ovarian tumors (n = 125) were used for comparison. RESULTS: Median plasma GDF-15 concentration for the endometrial cancer group was elevated (1,077 ng/L) as compared with pre- and postmenopausal controls (590 and 684 ng/L) and women with benign (591 ng/L) or borderline ovarian tumors (718 ng/L; all P < 0.001), but similar to the ovarian cancer group. In the large validation cohort of endometrial carcinomas, high plasma GDF-15 was significantly associated with International Federation of Gynecology and Obstetrics (FIGO) stage III/IV disease, nonendometrioid histology, high grade, older age, postmenopausal status, and lymph node metastases (all P ≤ 0.001). High GDF-15 was also an independent predictor of poor disease-specific and recurrence-free survival. CONCLUSIONS: Based on findings indicated in a primary investigation set and confirmed in the large secondary validation set, we report for the first time plasma GDF-15 as a biomarker for endometrial cancer phenotype, including presence of lymph node metastasis and reduced survival. Its applicability as a predictor of metastatic nodes and in monitoring treatment of endometrial cancer needs to be further studied.
Authors: Ray O Bahado-Singh; Amit Lugade; Jayson Field; Zaid Al-Wahab; BeomSoo Han; Rupasri Mandal; Trent C Bjorndahl; Onur Turkoglu; Stewart F Graham; David Wishart; Kunle Odunsi Journal: Metabolomics Date: 2017-12-01 Impact factor: 4.290
Authors: Toshihiko Tanno; Yiting Lim; Qiuju Wang; Marta Chesi; P Leif Bergsagel; Geoff Matthews; Ricky W Johnstone; Nilanjan Ghosh; Ivan Borrello; Carol Ann Huff; William Matsui Journal: Blood Date: 2013-12-17 Impact factor: 22.113
Authors: Balabhadrapatruni V S K Chakravarthi; Darshan S Chandrashekar; Sumit Agarwal; Sai Akshaya Hodigere Balasubramanya; Satya S Pathi; Moloy T Goswami; Xiaojun Jing; Rui Wang; Rohit Mehra; Irfan A Asangani; Arul M Chinnaiyan; Upender Manne; Guru Sonpavde; George J Netto; Jennifer Gordetsky; Sooryanarayana Varambally Journal: Mol Cancer Res Date: 2017-10-12 Impact factor: 5.852